MedNous | Business of medical innovation

Evernow Publishing Ltd Privacy Policy. Read more.

Free featured article

New start for MorphoSys

Country

Germany

MorphoSys AG ended the first half year poised to take over development of a new group of cancer drugs and potentially expand the indications for its first marketed product Monjuvi. The change comes as the company completes the acquisition of Constellation Pharmaceuticals Inc and advances trials for new uses of Monjuvi, its wholly-owned drug for refractory diffuse large B cell lymphoma. “We are writing the next chapter in our company’s history,” the MorphoSys chief executive Jean-Paul Kress, told investors during a briefing on 29 July.

Sanofi completes acquisitions in Q2

Country

France

Sanofi SA completed three acquisitions in the second quarter, signalling a new direction for research and development and potentially lifting the company’s dependence on sales of the immunology drug Dupixent. Acquisitions of Kiadis Pharma, a cell therapy company; Kymab Group, an antibody developer; and Tidal Therapeutics, a company with messenger RNA (mRNA) technology, were completed in April.

GSK pulls ahead in Q2

Country

United Kingdom

GlaxoSmithKline Plc pulled ahead in the second quarter recording a rise in turnover of 6% to £8.1 billion. This followed a double-digit decline in the first three months of the year. Operating profit for the latest quarter was £1.7 billion, down by 41% from the previous year, when the company recorded one-off income from several asset disposals.